News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Friday, Pfizer Inc. (PFE) announced that its gene therapy Beqvez also known as fidanacogene elaparvovec-dzkt has been approved by the FDA for treating adults with moderate to severe hemophilia B who undergo regular prophylaxis and is facing a current life-threatening bleed.
The company indicated that the FDA's decision was influenced by data from the BENEGENE-2 trial, a Phase 3 study that investigated the efficacy and safety of Beqvez in adult males between 18 and 65 years old with moderately severe to severe hemophilia B.
Pfizer also mentioned that Beqvez is undergoing evaluation by the European Medicines Agency and has recently been given the green light in Canada.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services..
E-mail: 24_support@just2trade.online
